Navigation Links
Lorus Therapeutics Announces Publication of a Clinical Study Demonstrating Encouraging Results with LOR-2040 in Combination with Cytarabine in Patients with Acute Myeloid Leukemia (AML)
Date:7/2/2008

- Study also points to potential of pre-treatment R2 levels as a possible

predictor of clinical activity -

TORONTO, July 2 /PRNewswire-FirstCall/ - Lorus Therapeutics Inc. (TSX: LOR, AMEX: LRP) ("Lorus" or the "Corporation"), a biopharmaceutical company specializing in the research and development of pharmaceutical products and technologies for the management of cancer, today announced publication by an Ohio State University (OSU) clinical team of a paper entitled "Phase I Study of GTI-2040, an Antisense to Ribonucleotide Reductase, in Combination with High-Dose Cytarabine in Patients with Acute Myeloid Leukemia" (Clinical Cancer Research 2008; 14 (12): 3889-3895). This was the first clinical study in AML with GTI-2040, now known as LOR-2040.

The primary author, Dr Rebecca Klisovic and the Principal Investigator, Dr Guido Marcucci, in the Division of Hematology and Oncology at OSU carried out the study under the sponsorship of the National Cancer Institute (NCI) Cancer Therapy Evaluation Program (CTEP). Lorus is collaborating with the Division of Cancer Treatment and Diagnosis, NCI on the development of LOR-2040 under a Clinical Trials Agreement. All patients in the study received LOR-2040 and high dose cytarabine in therapeutic doses within a dose escalating design, which determined a well-tolerated recommended Phase II dose.

In this study, the authors examined the relationship of the targeted activity of LOR-2040 to clinical responses in AML patients less than 60 years of age. Downregulation of R2, the target of LOR-2040, after 24 hours of LOR-2040 was statistically significant and was associated with complete remission. The authors have also now reported for the first time that outcomes of complete response were associated with high pre-treatment levels of R2, which were statistically significant compared to nonresponders. This finding suggests that pre-treatment R2 levels may be a predictor of response, and provid
'/>"/>

SOURCE Lorus Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Lorus Advances Clinical Development of GTI-2040 Combined with Ara-C in Acute Myeloid Leukemia
2. Lorus Therapeutics Appoints Peter Korth as Chief Financial Officer
3. Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin(R)
4. Lorus Therapeutics presents new findings for the anticancer drugs LOR-253 and LOR-2040
5. Lorus initiates development program exploring novel route of administration for LOR-2040
6. Lorus Therapeutics Strengthens Its Senior Management Team Through Internal Promotions
7. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
8. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
9. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
10. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
11. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2015)... Proove Biosciences , a commercial ... to announce the launch of Proove Non-Opioid ... 62 genetic variations to predict good versus poor ... non-opioid pain medications, namely ibuprofen (brand name Advil, ... Xanax) and acetaminophen (brand name Tylenol). , ...
(Date:4/23/2015)... Texas (PRWEB) April 23, 2015 ReliantHeart's ... True Flow (blood flow through the device) in real ... by Numerex, the world’s leading provider of Machine to ... , True Flow via VADLink.com can ... there is any drop in flow below a minimum ...
(Date:4/22/2015)... , April 22, 2015 /PRNewswire/ - BioAmber Inc. (NYSE and EURONEXT Paris:BIOA) today ... first quarter 2015 on Thursday, May 7, 2015 after ... a webcast and conference call for 4.30 pm ET ... Live audio of the conference call will be ... investors, members of the news media and the general ...
(Date:4/22/2015)... 2015 2015 HIMSS Annual Conference & ... of the 9th annual Venture+ Forum pitch competition for ... selected to deliver live pitch presentations to a panel ... HIMSS15 held last week in Chicago ... professionals and 1,200 exhibiting companies from around the world, ...
Breaking Biology Technology:Proove Biosciences Launches World’s First Test to Predict Responders to Commonly Prescribed Non-Opioid Pain Medications 2Proove Biosciences Launches World’s First Test to Predict Responders to Commonly Prescribed Non-Opioid Pain Medications 3BioAmber Announces Webcast of Fiscal First Quarter 2015 Financial Results 2TowerView Health Named Venture+ Forum Pitch Competition Winner At HIMSS15 2TowerView Health Named Venture+ Forum Pitch Competition Winner At HIMSS15 3
(Date:3/30/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/lc9bnl/global_gesture ) has ... Market in Automotive Sector 2014-2018" report to their ... Recognition market in Automotive Sector to grow at a ... Gesture recognition is the ability of a device to ... Gesture recognition technology can be 2D-based or 3D-based. It ...
(Date:3/24/2015)... 24, 2015 Research and Markets ( http://www.researchandmarkets.com/research/kvdtcw/face_and_voice ) ... - Global Strategic Business Report" report to their offering. ... Biometrics in US$ Thousands by the following Segments: Face Biometrics, and ... Canada , Japan , ... Middle East & Africa , and ...
(Date:3/23/2015)... , March 23, 2015 SoundView Technology Group issues ... (NASDAQ: NXTD ) Wocket smart wallet. SoundView was one of ... on their experience with the Wocket in multiple scenarios and ... Whole Foods and other retailers, making both debit and credit ... also says, "If the company meets their plans in ...
Breaking Biology News(10 mins):Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 3Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 4Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 5Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 6Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 3Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 4
... Stat1, which is involved in cellular immune signaling, scientists have ... efficient. This old protein with a new twist may eventually ... , Stat1 is involved in immune responses that are initiated ... the cells of the immune system in response to challenges ...
... have demonstrated that the brains of alcoholics are ... brains. Symposium speakers at the October 2004 Congress ... Alcoholism in Mannheim, Germany reviewed what is known ... alcohol-related brain shrinkage. Proceedings are published in the ...
... require accurate transmission. Big genes are especially challenging ... lie between long stretches of non-coding elements (introns). ... pasted together to form a template for proteins ... can reduce the expression of a functional protein ...
Cached Biology News:Engineered molecule amplifies body's immune response 2Engineered molecule amplifies body's immune response 3Investigating 'brain shrinkage' in alcoholics 2Investigating 'brain shrinkage' in alcoholics 3Investigating 'brain shrinkage' in alcoholics 4Investigating 'brain shrinkage' in alcoholics 5Carnegie Mellon University research reveals how cells process large genes 2Carnegie Mellon University research reveals how cells process large genes 3
... Sciences can provide custom microplate coating using advanced automated high ... of plate formats. We can also accommodate virtually any lot ... 0.5-320 L):, , 8 ... well microplate, 384 well microplate, ...
... HRP Conjugation Kits are based on ... that are consistent and reproducible. This ... conjugate your protein or antibody, including ... buffer. Activated HRP is supplied ...
... ester can be used to ... The covalently bound acridinium NHS ... the presence of hydrogen peroxide. ... be used as a detection ...
... hold up to 6 strain chambers with precise ... use design ensures that cells grow over long ... compression. This unit allows you to control the ... 64 unique strain settings. The instrument fits in ...
Biology Products: